Asabys Partners

Quibim, headquartered in Valencia, Spain, is a leader in whole-body medical imaging analysis, providing innovative AI-based image processing technologies. Its products, utilized by pharmaceutical companies and research teams globally, focus on extracting quantitative information from radiological images. Quibim Precision®, the company's whole-body imaging ecosystem, supports a variety of applications, from disease detection to monitoring the effectiveness of new treatments. By employing an AI-first approach, Quibim enables partners to accurately identify pathologies across different body parts and imaging modalities, ultimately enhancing the diagnosis of high-incidence illnesses and assessing treatment outcomes. This commitment to leveraging advanced imaging biomarkers contributes significantly to improving human health.

Splice Bio is a biotechnology company based in Barcelona, Spain, focused on developing innovative gene therapies using its proprietary intein platform technology. Founded in 2012 and originally named Proteodesign, S.L., the company aims to address the needs of patients suffering from incurable genetic diseases. The intein platform, developed from research in the Muir Lab at Princeton University, seeks to overcome two significant limitations of traditional adeno-associated virus (AAV) therapies: it enhances the capacity for larger gene delivery and broadens the range of tissues that can be targeted for treatment.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.

Koa Health B.V., founded in 2018 and based in Amsterdam with additional offices in Barcelona, the United States, and the United Kingdom, develops digital solutions aimed at enhancing mental well-being for employees. The company provides a range of products that are informed by the latest clinical research and technology. Its offerings include the koa foundation application, which supports early symptom management and mild mental health issues, and Mindset, a chat-based platform for private mental health support. Koa Health’s solutions encompass prevention, prediction, and treatment, featuring a library of evidence-based activities designed to address various mental health challenges, such as stress management, sleep improvement, and confidence building. By delivering scalable and affordable care, Koa Health aims to make mental health support accessible and effective for individuals and organizations alike.

Splice Bio is a biotechnology company based in Barcelona, Spain, focused on developing innovative gene therapies using its proprietary intein platform technology. Founded in 2012 and originally named Proteodesign, S.L., the company aims to address the needs of patients suffering from incurable genetic diseases. The intein platform, developed from research in the Muir Lab at Princeton University, seeks to overcome two significant limitations of traditional adeno-associated virus (AAV) therapies: it enhances the capacity for larger gene delivery and broadens the range of tissues that can be targeted for treatment.

Origo Biopharma S.L. is a biotechnology company founded in 2017 and headquartered in San Cibrao das Viñas, Spain. The company specializes in the research and development of immunotherapeutic products aimed at treating severe diseases associated with TGF-β signaling dysfunction, particularly in gastrointestinal and lung conditions. Origo Biopharma focuses on developing organ-restricted drugs to meet unmet medical needs related to cancer and fibrosis, striving to provide effective treatments for these challenging health disorders.

Ona Therapeutics, S.L. is a biotechnology company based in Barcelona, Spain, founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren. The company focuses on the discovery and development of therapeutic biologics aimed at targeting tumor metastatic-initiating cells and lipid metabolism. Ona Therapeutics develops therapies that block fat metabolism pathways in animal models of cancer and inhibit cells responsible for metastasis. This approach holds the potential to prevent the development of malignant tumors and eliminate existing ones, allowing healthcare institutions to address various metastatic cancers, including those of the oral cavity, breast, ovary, stomach, bladder, prostate, and melanoma.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Anaconda BioMed is a medical technology company based in Barcelona, Spain, founded in 2015 by Dr. Ofir Arad and Dr. Marc Ribó. The company specializes in developing advanced healthcare devices, particularly focused on neuro-thrombectomy systems for the treatment of acute ischemic stroke (AIS). Its flagship product, the ANCD BRAIN™, is a third-generation stented aspiration thrombectomy system that comprises a delivery catheter, a funnel-shaped aspiration catheter, and a stent retriever. This innovative system is designed to conform to the artery and effectively arrest blood flow, facilitating the full extraction of thrombus without fragmentation. Anaconda BioMed aims to provide patients with immediate treatment options for stroke, significantly reducing the risk of fatality associated with this critical medical condition.

Amelia Virtual Care is a mental health technology company with offices in Barcelona and Mountain View, specializing in a comprehensive virtual reality platform designed for mental health treatment. This platform enables professionals to address a variety of mental health disorders, including phobias, anxiety, and depression. With a workforce of over 60 employees, Amelia has successfully delivered more than 200,000 VR therapy sessions, primarily in the United States, which serves as its main market. The company's innovative platform includes multiple features and user-friendly controls, facilitating effective therapy sessions. Recent financing and a new management team are expected to enhance Amelia's growth and strengthen its clinical evidence and commercial activities.